Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

potential

6 posts
RRoche
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
Read More

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

  • 2026-04-22
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is…
AABB
ABB Appoints Automotive Veteran to Lead Robotics Division Ahead of Potential Spin-Off
Read More

ABB Appoints Automotive Veteran to Lead Robotics Division Ahead of Potential Spin-Off

  • 2026-04-03
ABB appoints Marc-Oliver Nandy to head its key robotics division in Germany, Austria, and Switzerland, leveraging his automotive…
BBern
Bern Cantonal Bank Faces Potential Credit Rating Review
Read More

Bern Cantonal Bank Faces Potential Credit Rating Review

  • 2026-03-29
Bern, Cantonal 29.03.2026 – 00:37:34 | boerse-global.de Zurich Cantonal Bank places Bern Cantonal Bank’s…
RRoche
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
Read More

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

  • 2026-03-03
F. Hoffmann-La Roche Ltd Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory…
RRoche
Strong Sales Growth and Strategic ...
Read More

Strong Sales Growth and Strategic …

  • 2026-02-24
Group Sales Growth: 7% overall; 9% excluding COVID-19 impact. Core Operating Profit Growth: 14% increase. Core Operating Margin:…
NNovartis
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Read More

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

  • 2026-02-23
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
Switzerland
www.europesays.com